Brain cancer update | AIMS Institute

Brain cancer update July 12, 2024
Leanna Standish

IV CURCUMIN

AIMS Institute’s integrative oncology team is investigating the therapeutic effects of intravenous curcumin in treating the most aggressive type of brain cancer, called glioblastoma. Curcumin is the molecule present in turmeric root that has anticancer activity. Curcumin has been shown in cell culture experiments to cause the programmed death of glioblastoma cells. We use IV curcumin in order to provide sufficient levels of curcumin to the brain that will slow tumor growth. Our brain cancer patients are enrolled in AIMS Institute’s IRB-approved study called the AIMS CANCER OUTCOMES STUDY. Last year we presented our first results of IV curcumin in glioblastoma to the SWEDISH HOSPITAL NEUROLOGY SEMINAR and at the ONCOLOGY ASSOCIATION OF NATUROPATHIC ONCOLOGY annual meeting.

Currently, Drs. Jaffe, Anthony, and Standish are preparing a scientific manuscript for a medical journal that summarizes our findings.

LIQUID BIOPSY IS NOW AVAILABLE FOR BRAIN CANCER

AIMS Institute utilizes cutting-edge cancer genetic sequencing to help us understand the unique biology of each patient’s cancer. Liquid biopsy refers to a blood test that sequences the DNA in tumor cells that circulate in the blood. Until 2024 there has never been a liquid biopsy for brain cancer. Thanks to BILLION TO ONE a cancer gene company there is now a blood test for brain cancer. These blood tests help us know what the best treatment might be and also whether the current treatment is working for the patient.

Latest Blog Posts

Envisioning Drug Peace in the Entheogenic Reformation:

Incorporating the Spiritual Geography of Psychoactives in Post-Prohibition Public Health Greetings, I am Sunil Aggarwal, a doctor and medical geographer and a member of the Sacred Garden Community. I hail from Oklahoma, a child of Indian Immigrants, and I live today in Seattle, which rests on the unceded territory of the co-Salish Duwamish People, and I am so honored to join you here in Portland, a city which rests on the traditional village sites of the Multnomah, Wasco, Cowlitz, Kathlamet, Clackamas, Bands of Chinook, Tualatin, Kalapuya, Molalla, and many others who made their homes along the Columbia River. The title ...

The Healing Mind: Integrating Mental Health into Cancer Care

By: Atara Jaffe, ND Feelings of anxiety and depression are common and often overlooked aspects of an individual’s experience in the cancer care process. At AIMS Institute, we provide integrative mental health care through a variety of modalities to approach body and mind. Our oncology team members that have proficiency in mental health include: Dr. Atara Jaffe, ND, Dr. Ksenia Malarkey, ND, Dr. Raushanah Najeeullah, ND, Dr. Monet Anthony, ND, Dr. Leanna Standish, ND, PhD. Our other team members also have experience and background with mental health services including: Dr. Emily Whinkin, ND, MS, Dr. Sunil Aggarwal, MD, PhD, Dr. ...

Impacts to Anxiety, Depression, and Psycho-Spiritual Metrics after Ketamine-Assisted Psychotherapy in Palliative Care Patients at the AIMS Institute

Author: Thomas Luedeke, Seattle University https://scholarworks.seattleu.edu/dnp-projects/95/ Date of Award 2024 Document Type Project College/School College of Nursing Degree Name Doctor of Nursing Practice (DNP) Project Mentor Therry Rose Eparwa Readers Conor Watters Abstract There is considerable evidence that palliative care patients disproportionately experience anxiety, depression, and existential distress related to their chronic illnesses. Additionally, conventional therapies tend to be less effective in the treatment of this patient population. As such, research is being conducted into novel therapies. One of the promising therapies currently under active investigation is ketamine-assisted psychotherapy (KAP) which involves a combination of the administration of the dissociative anesthetic ...